Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

Academic Article

Abstract

  • We examined whether reduced levels of Apolipoprotein A-l (apoA- I) in ovarian cancer patients are causal in ovarian cancer in a mouse model. Mice expressing a human apoA-l transgene had (i) increased survival (P < 0.0001) and (ii') decreased tumor development (P < 0.01), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells). ApoA-l mimetic peptides reduced viability and proliferation of ID8 cells and cis-platinum-resistant human ovarian cancer cells, and decreased ID-8 cell-mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally. Serum levels of lysophosphatidic acid, a well-characterized modulator of tumor cell proliferation, were significantly reduced (>50% compared with control mice, P < 0.05) in mice that received apoA-l mimetic peptides (administered either subcutaneously or orally), suggesting that binding and removal of lysophosphatidic acid is a potential mechanism for the inhibition of tumor development by apoA-l mimetic peptides, which may serve as a previously unexplored class of anticancer agents.
  • Digital Object Identifier (doi)

    Author List

  • Su F; Kozak KR; Imaizumi S; Gao F; Amneus MW; Grijalva V; Ng C; Wagner A; Hough G; Farias-Eisner G
  • Start Page

  • 19997
  • End Page

  • 20002
  • Volume

  • 107
  • Issue

  • 46